U.S. Markets closed

Keryx Biopharmaceuticals, Inc. (KERX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.95+0.03 (+0.43%)
At close: 4:00PM EDT
People also watch
AEZSCLDXARNAACADOREX
  • s
    scott e
    scott e
    SYM = $1.06, IMS = 1126. Thanks to folks on Stocktwits
  • g
    gwells
    gwells
    Zacks article cautions buying Keryx because it's gone up so much this year citing manufacturing issues. Seriously?? Old news. What a joke.
  • B
    Barry
    Barry
    Increased mortality

    Anemia is a risk factor for mortality among patients with ND-CKD. In the CKD-ROUTE study, researchers found that patients who had anemia with or without iron deficiency had a 3-fold increased risk of all-cause mortality and a nearly 4-fold increased risk of cardiovascular mortality compared with controls who had neither anemia nor iron deficiency.7 In the anemic patients without iron deficiency, the proportion of those who were prescribed erythropoiesis-stimulating agents (ESAs) rose from 31.1% at baseline to 68.9% at 6 months. In patients with both iron deficiency and anemia, the proportion of those prescribed iron supplementation increased from 18.5% at baseline to 48.1% at 6 months. The authors concluded that iron prescriptions for anemic patients with iron deficiency did not sufficiently increase compared with the increase in ESA prescriptions. "These results suggest that it is necessary to assess iron deficiency and to appropriately use iron supplementation," the authors concluded.

    Inflammation and iron assessment

    TSAT and serum ferritin are the most widely used laboratory parameters for assessing iron status, but both of these markers are subject to excessive biological variability and require caution when used to guide iron supplementation in patients with CKD.9 These markers show relatively poor correlation with bone marrow stores and erythropoietic response to iron treatment.1 Underlying inflammation, which is common in patients with CKD, complicates the diagnosis of iron-deficiency anemia. Inflammation increases levels of hepcidin, a peptide hormone synthesized mainly in the liver. It is a key regulator of iron metabolism that inhibits release of iron from macrophages and hepatocytes and blocks intestinal absorption of dietary iron. TSAT values usually are low (less than 20%) in patients with high hepcidin levels due to inflammation because iron is not released for binding to transferrin. Ferritin values rise to above 100 ng/mL, possibly indicating adequate body stores, the presence of inflammation, or both.1 Patients with functional iron-deficiency anemia respond to iron supplementation, which helps to distinguish it from anemia caused by inflammation.1 Szu-Chun Hung, MD, and Der-Cherng Tarng, MD, PhD, pointed out in an editorial in the American Journal of Kidney Diseases that bone marrow iron reflects stored iron, not the iron readily available for erythropoiesis in patients receiving ESAs. "To date, the only definite way to show functional iron deficiency in clinical practice is to evaluate the erythropoietic response to iron administration."10

    Alternative and novel iron biomarkers

    Although TSAT and serum ferritin are the most widely used iron biomarkers, other laboratory tests available to US clinicians may provide more accurate assessments of iron status. These include reticulocyte hemoglobin content (CHr), percentage of hypochromic red cells (PHRC), and soluble transferrin receptor (sTfR).

    lthough TSAT and serum ferritin are the most widely used iron biomarkers, other laboratory tests available to US clinicians may provide more accurate assessments of iron status. These include reticulocyte hemoglobin content (CHr), percentage of hypochromic red cells (PHRC), and soluble transferrin receptor (sTfR).

    CHr is a measure of the hemoglobin content of reticulocytes, newly formed red blood cells (RBCs). As Jay B. Wish, MD, explained in a review article, CHr provides a "snapshot of how much iron was available for RBC production in a clinically relevant timeframe."11

    PHRC assays measure the hemoglobin concentration in erythrocytes rather than hemoglobin content. It takes into account the absolute amount of hemoglobin as well as the size of RBCs. As Dr Wish points out, the major impediment to the use of this test in the United States is that erythrocytes tend to expand during storage. Most of the large dialysis chains ship blood samples to national laboratories for analyses, and there is considerable storage time from when blood samples are collected until they are analyzed.11

    The sTfR test is based on the fact that iron deficiency will cause erythroblasts in the bone marrow to increase presentation of membrane transferrin receptor. "If a patient is not receiving sufficient iron and erythropoiesis is being stimulated by an ESA, then increased transferrin receptors will become expressed on the erythroblasts, some of which come off and will be detectable in the circulation," Dr Wish explained.11

    Hepcidin

    As mentioned previously, elevated levels of hepcidin decrease absorption of dietary iron and impair release of iron stores in hepatocytes and macrophages. These elevated levels may be the result of underlying inflammation as well as diminished kidney function. As kidney function deteriorates, the ability to clear hepcidin may decrease, leading to higher hepcidin levels.12 Evidence suggests that hepcidin may be a useful biomarker of iron status. As Guido D'Angelo, MD, of Azienda Ospedaliera S.Antonio Abate di Callarate, Varese, Italy, observed in a review article,13 serum and urinary hepcidin concentrations in pure iron-deficiency anemia are significantly decreased and are even undetectable by some currently used methods. "Even in the absence of anemia, hepcidin appears to be a sensitive indicator of iron deficiency," he noted. "Moreover, compared to hematocrit or hemoglobin, a decrease in hepcidin is an early marker of iron deficiency together with transferrin saturation and decreased ferritin.
  • 2
    2Cents
    2Cents
    It doesn't matter what Zacks says or what any of us longterm holders here have to say. It all comes down to the FDA decision in early Nov. Best wishes to all longs and thoughts and prayers to the millions of people impacted by recent storms in TX, FL and the Caribbean islands.
  • C
    Chris
    Chris
    Google finance Just rehashed that Zacks just gave Kerx a sell rating.Give me a break those losers at Zacks did that many weeks ago.Then that lying article put out yesterday.Should be investigated for putting out misinformed lying information
  • B
    Bert
    Bert

    DOPPS: Infection control practices for peritoneal dialysis patients vary by country, peritonitis rates vary greatly between facilities

    ....Iron-based phosphate binders: The prescription of new iron-based phosphate binders (ferric citrate and sucroferric oxyhydroxide) has increased steadily among hemodialysis patients, from 2% in 2015 to over 7% in June 2017. Prescription of sevelamer (a non-metal-based phosphate binder) has decreased by a similar amount during the same time period, while prescription of calcium-based phosphate binders have remained unchanged.

    And please do mea favor OPEN THE LINK you will see why ;-)

    https://www.nephrologynews.com/dopps-infection-control-practices-peritoneal-dialysis-patients-vary-country-peritonitis-rates-vary-greatly-facilities/

    DOPPS: Infection control practices for peritoneal dialysis patients vary by country, peritonitis rates vary greatly between facilities - Nephrology News & Issues
    Researchers from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor (DPM) will host a web conference on Thursday, September 21, 2017 at 3 ...
    www.nephrologynews.com
  • R
    Renman95
    Renman95
    Zacks zucks!
  • B
    Bert
    Bert

    ADVANCES IN THE
    TREATMENT OF
    ANEMIA IN
    PATIENTS WITH
    CHRONIC KIDNEY
    DISEASE

    by
    Pablo E. Pergola, MD PhD
    Director of Research
    Renal Associates PA
    San Antonio, Texas
    and
    Clinical Associate Professor of
    Medicine
    Division of Nephrology
    UT Health San Antonio

    NICE PRESENTION with a very good overview about treatment options, including Auryxia of course

    http://txkidney.org/wp-content/uploads/2017/04/Advances-in-Anemia-Care.pdf?x15235

  • g
    gerald
    gerald
    FDA has always had Keryx by the @alls; from the time they made them put that stupid label warning on Auryxia to now when they hold up a simple decision on a very simple drug with some of the most straight forward data they deal with for 10 frigging months; our taxpayer money being well spent on starbucks for FDA employees who appear to take a break all day long....you kidding?
  • G
    Gary
    Gary
    A tale of two stocks! In Oct. of 2014 POS KERX was $14 to $15 a share. In that same time frame NVDA was was even lower $13 to $14 a share. Which stock would you rather have now. This is why you leave a loser like JERX and buy another stock. I wish I got NVDA at those prices but I did buy it under $100 and it is on its way to $200 while POS KERX is still 2x under its 2014 mark.Stop dreaming and move on
    Imagekarl-shakur
  • M
    Mike
    Mike
    The competitors got this iron overload warning on the Auryxia label, but according to the phase3 clinicals there was no iron overload, except for people also taking IV iron. This was a warning that shoul;d have said if you are taking Auryxia you should stop IV iron. Dr. Davis had said in her research iron overload did not exist in her studies of the phase 3 trials. I am sure this hurt Auryxia sales more than management did.
  • h
    hai
    hai
    Going the wrong way again.
  • B
    Brian
    Brian
    I have tried multiple times to post a link from an interesting patient comment that I found on Stocktwits, and Yahoo will not let it post. Check out Stocktwits for KERX, and look for a link starting patient(dot)info.
  • z
    zippynj
    zippynj
    lwts continue onward and upward!!!!
  • L
    Lily
    Lily

    Is KERX undervalued? This sort of setup suggests potential upside... https://hotstocks123.blogspot.com just allerted a new stock - it beats having to dig online yourself for new stock ideas.

    Hot Stocks
    hotstocks123.blogspot.com
  • k
    kenneth
    kenneth
    Seems to want to hang right at 7
  • L
    Liz
    Liz
    Auryxia and Iron overdose - from FDA reports

    Summary

    There is no Iron overdose reported by people who take Auryxia yet. This review analyzes which people have Iron overdose with Auryxia. It is created by eHealthMe based on reports from FDA, and is updated regularly.
  • E
    Elvis
    Elvis
    Lets see a run over $8 this week
  • B
    Bert
    Bert

    AURYXIA
    IRON OVERLOAD WARNING LABEL

    Here are the official entries of adverse effects in conjunction with iron overload reported to the FDA and documentated in the database EHEALTHME

    AURYXIA
    http://www.ehealthme.com/ds/auryxia/iron-overdose/
    http://www.ehealthme.com/ds/auryxia/iron-overload/

    All approved drugs in the US
    http://www.ehealthme.com/side-effect/iron-overload/

    There is one word for such a "high" quantity of iron overload reports: UNREMARKABLE

    Will you have Iron overdose with Auryxia - from FDA reports - eHealthMe
    www.ehealthme.com
  • E
    Elvis
    Elvis
    where is the PR team for this company? We should at $10